Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9

Cancer Genetics and Cytogenetics

Volumn 194, Issue 1, 2009, Pages 30-37

  Bennour, Ayda ^a   Sennana, Halima ^a   Laatiri, Mohamed Adnène ^a   Elloumi, Moez ^b   Khelif, Abderrahim ^a   Saad, Ali ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

^b HEDI CHAKER HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW; CHROMOSOME 9; CHROMOSOME 9Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GC RICH SEQUENCE; HUMAN; HUMAN TISSUE; LEUKEMOGENESIS; MUTATIONAL ANALYSIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS;

CHROMOSOME BANDING; CHROMOSOME DELETION; CHROMOSOME PAINTING; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; GENETIC VARIATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PHILADELPHIA CHROMOSOME; TRANSLOCATION, GENETIC;

EID: 69749092286     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.05.010     Document Type: Article

References (43)

1. Deininger M.W.N., Goldman J.M., and Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 96 (2000) 3343-3356
2. Goldman J.M., and Melo J.V. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 349 (2003) 1451-1464
3. Reddy K.S., and Sulcova V. A FISH study of variant Philadelphia rearrangements. Cancer Genet Cytogenet 118 (2000) 121-131
4. Gorusu M., Benn P., Li Z., and Fang M. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet 173 (2007) 97-106
5. Bennour A., Sennana H., Laatiri M.A., Khelif A., and Saad A. A masked BCR/ABL rearrangement in a case of chronic myeloid leukemia with translocation t(3;9)(p14;q34). Cancer Genet Cytogenet 181 (2008) 72-74
6. Todorić-Zivanović B., Marisavljević D., Surace C., Cemerikić V., Marković O., Krtolica K., Tatomirović Z., Cikota B., Magić Z., and Rocchi M. A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1). Cancer Genet Cytogenet 166 (2006) 180-185
7. Naumann S., and Decker H.J. Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia. Cancer Genet Cytogenet 147 (2003) 18-22
8. Fitzgerald P.H., and Morris C.M. Complex chromosomal translocations in the Philadelphia chromosome leukemias: serial translocations or a concerted genomic rearrangements?. Cancer Genet Cytogenet 57 (1991) 143-151
9. Soenen V., Viguié F., Laï J.L., Andrieux J., Corm S., Roche-Lestienne C., and Fi-LMC Group. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL or BCR deletion status or response to imatinib therapy. Cancer Genet Cytogenet 182 (2008) 95-102
10. Yehuda O., Abeliovich D., Ben-Neriah S., Sverdlin I., Cohen R., Varadi G., Orr R., Ashkenazi Y.J., Heyd J., Lugassy G., and Ben Yehuda D. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. Cancer Genet Cytogenet 114 (1999) 100-107
11. Morris C.M., Heisterkamp N., Groffen J., and Fitzgerald P.H. Entire ABL gene is joined to 5′- BCR in some patients with Philadelphia-positive leukemia. Blood 78 (1991) 1078-1084
12. Huret J.L. Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia. Hum Genet 85 (1990) 565-568
13. Wang Y.L., Bagg A., Pear W., Nowel P.C., and Hess J.L. Chronic myelogenous leukemia: laboratory diagnosis and monitoring. Genes Chromosomes Cancer 32 (2001) 97-111
14. Zagaria A., Anelli L., Albano F., Vicari L., Schiavone E.M., Annunziata M., Pane F., Liso V., Rocchi M., and Specchia G. Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia. Cancer Genet Cytogenet 167 (2006) 97-102
15. Douet-Guilbert N., Morel F., Quemener S., Maguer A., Le Bris M.J., Morice P., Berthou C., and De Braekeleer M. Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia. Cancer Genet Cytogenet 170 (2006) e89-e92
16. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., Bench A., Champion K., Huntly B., and Green A.R. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 (2000) 738-743
17. Huntly B.J., Reid A.G., Bench A.J., Campbell L.J., Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P., and Green A.R. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 (2001) 1732-1738
18. Kolomietz E., Al-Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J., and Squire J.A. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97 (2001) 3581-3588
19. Huntly B.J., Guilhot F., Reid A.G., Vassiliou G., Hennig E., Franke C., Byrne J., Brizard A., Niederwieser D., Freeman-Edward J., Cuthbert G., Bown N., Clark R.E., Nacheva E.P., Green A.R., and Deininger M.W. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 102 (2003) 2205-2212
20. Beran M., Cao X., Estrov Z., Jeha S., Jin G., O'Brien S., Talpaz M., Arlinghaus R.B., Lydon N.B., and Kantarjian H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 4 (1998) 1661-1672
21. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
22. ISCN. 2005: An International System for Human Cytogenetic Nomenclature. Shaffer LG, Tommerup N, editors. Karger, 2005.
23. De Melo V.A., Milojkovic D., Marin D., Apperley J.F., Nacheva E.P., and Reid A.G. Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements. Cancer Genet Cytogenet 182 (2008) 111-115
24. Lyall J.M., Brodie G.N., and Garson O.M. A variant chromosomal translocation found in a series of 24 patients with Philadelphia positive chronic granulocytic leukaemia. Aust N Z J Med 8 (1978) 288-289
25. Kolitz J.E., Schulman P., Kardon N., Budman D.R., Vinciguerra V.P., Broekman A., and Degnan T.J. A complex variant Philadelphia (Ph1) chromosome translocation involving chromosomes no. 11, 14, and 22 in a case of chronic myelogenous leukemia. Cancer Genet Cytogenet 4 (1981) 185-188
26. Potter A.M., Watmore A.E., Cooke P., Lilleyman J.S., and Sokol R.J. Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia. Br J Cancer 44 (1981) 51-54
27. Testa J.R., Jumamoy L.M., and Wiernik P.H. Variant Philadelphia chromosome translocations in two patients with chronic myelogenous leukemia. Cancer Genet Cytogenet 7 (1982) 79-84
28. Bernstein R., Pinto M.R., Wallace C., Penfold G., and Mendelow B. The incidence, type, and subsequent evolution of 14 variant Ph1 translocations in 180 South African patients with Ph1-positive chronic myeloid leukemia. Cancer Genet Cytogenet 12 (1984) 225-238
29. De Braekeleer M. Variant Philadelphia translocations in chronic myeloid leukemia. Cytogenet Cell Genet 44 (1987) 215-222
30. Haltrich I., Kost-Alimova M., Kovacs G., Krivan G., Tamaska J., Klein G., Fekete G., and Imreh S. Jumping translocation of 17q11∼qter and 3q25∼q28 duplication in a variant Philadelphia t(9;14;22)(q34;q32;q11) in a childhood chronic myelogenous leukemia. Cancer Genet Cytogenet 164 (2006) 74-80
31. Sessarego M., Fugazza G., Bruzzone R., Ballestrero A., Miglino M., and Bacigalupo A. Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11. Haematologica 85 (2000) 35-39
32. Espinoza J.P.M., Cárdenas V.J.P., Jiménez E.A.V., Angulo M.G., Flores M.A.E., and García J.R.G. A complex translocation (9;22;16)(q34;q11.2;p13) in chronic myelocytic leukemia. Cancer Genet Cytogenet 157 (2005) 175-177
33. Buda G., Orciuolo E., Cecconi N., Galimberti S., Cervetti G., and Petrini M. Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11). Leuk Res 31 (2007) 1765-1766
34. Loncarevic I.F., Römer J., Starke H., Heller A., Bleck C., Ziegler M., Fiedler W., Liehr T., Clement J.H., and Claussen U. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer 34 (2002) 193-200
35. Reid A.G., Huntly B.J., Grace C., Green A.R., and Nacheva E.P. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 121 (2003) 419-427
36. Fisher A.M., Strike P., Scott C., and Moorman A.V. Breakpoints of variant 9;22 translocations in chronic myeloid leukemia locate preferentially in the CG-richest regions of the genome. Genes Chromosomes Cancer 43 (2005) 383-389
37. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S., Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J., Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R., Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A., Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K., Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V., Brandon R., Cargill M., Chandramouliswaran I., Charlab R., Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K., Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z., Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A., Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V., Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B., Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J., Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C., Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L., Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S., Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A., Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D., Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L., Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N., Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S., Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F., Kline L., Koduru S., Love A., Mann F., May D., McCawley S., McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K., Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M., Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C., Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N., Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M., Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F., Guigó R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A., Mi H., Lazareva B., Hatton T., Narechania A., Diemer K., Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R., Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J., Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H., Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D., Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A., Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S., Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L., Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W., McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M., Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J., Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E., Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., and Zhu X. The sequence of the human genome. [Erratum in: Science 2001;292:1838]. Science 292 (2001) 1838
38. Martinelli G., Terragna C., Amabile M., Montefusco V., Testoni N., Ottaviani E., de Vivo A., Mianulli A., Saglio G., and Tura S. Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints. Hematologica 85 (2000) 40-46
39. Kong A., Gudbjartsson D.F., Sainz J., Jonsdottir G.M., Gudjonsson S.A., Richardsson B., Sigurdardottir S., Barnard J., Hallbeck B., Masson G., Shlien A., Palsson S.T., Frigge M.L., Thorgeirsson T.E., Gulcher J.R., and Stefansson K. A high-resolution recombination map of the human genome. Nat Genet 31 (2002) 241-247
40. Gilbert N., Boyle S., Fiegler H., Woodfine K., Carter N.P., and Bickmore W.A. Chromatin architecture of the human genome: gene-rich domains are enriched in open chromatin fibers. Cell 118 (2004) 555-566
41. Versteeg R., van Schaik B.D., van Batenburg M.F., Roos M., Monajemi R., Caron H., Bussemaker H.J., and van Kampen A.H. The human transcriptome map reveals extremes in gene density, intron length, GC content, and repeat pattern for domains of highly and weakly expressed genes. Genome Res 13 (2003) 1998-2004
42. Jeffs A.R., Benjes S.M., Smith T.L., Sowerby S.J., and Morris C.M. The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia. Hum Mol Genet 7 (1998) 767-776
43. El-Zimaity M.M., Kantarjian H., Talpaz M., O'Brien S., Giles F., Garcia-Manero G., Verstovsek S., Thomas D., Ferrajoli A., Hayes K., Nebiyou Bekele B., Zhou X., Rios M.B., Glassman A.B., and Cortes J.E. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 125 (2004) 187-195